Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder

2014-08-27 03:46:43 | BioPortfolio


The purpose of this research study is to evaluate the safety, tolerability, and efficacy (how well the drug works) of risperidone compared to placebo (an inactive drug) in the treatment of bipolar disorder with panic disorder or generalized anxiety disorder. Risperidone is currently approved by the United States Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar mania. Risperidone is not currently FDA approved for the treatment of bipolar hypomania with or without panic disorder or generalized anxiety disorder (the condition being investigated in this study).


Methods and Procedures:

This is a randomized, double-blind, placebo controlled, parallel-group, 3 site, 8-week trial of risperidone monotherapy in outpatient subjects with a lifetime bipolar I, II, or not otherwise specified (NOS) disorder, a lifetime panic or generalized anxiety disorder, and current, at least moderately, severe anxiety symptoms. Approximately 90 subjects will be enrolled to obtain 60 subjects who complete the 8-week trial. Subjects will be randomized to risperidone or placebo in a 1:1 ratio. No concomitant psychotropic medication will be allowed except for as needed (prn) lorazepam during the first two weeks for the management of affective and anxiety symptoms, and prn zolpidem and zaleplon throughout the study for the management of insomnia. Throughout the study, psychiatric scales will be used to assess psychiatric symptoms and the presence of treatment-emergent adverse events will be monitored and recorded.

Medication Dosing:

Risperidone will be administered at an initial dose of 0.5 to 1 mg/day and will be titrated upward to a dose considered optimal by the investigator based on the subject's clinical response and adverse events, but not to exceed 2.0 mg/day by the end of the second week. Subsequently, risperidone may be increased based on clinical response and tolerability to a maximum of 4.0 mg/day. As needed study-prescribed (prn) use of lorazepam will be allowed for the management of affective and anxiety symptoms for the first two weeks of the study; a maximum of 2 mg per day will be allowed during the first week, and a maximum of 1 mg per day will be allowed during the second week. During the second week, the subject must be tapered off the lorazepam. For the final six weeks of the study, no lorazepam will be permitted. Zolpidem (10-20 mg/day) or zaleplon (10-20 mg/day) will be allowed for management of insomnia, and benztropine (0.5 - 3.0 mg/day) will be allowed for management of extrapyramidal symptoms. The latter three agents will be permitted throughout the study.

From week 2 on, any medications with psychotropic effects are prohibited.

Screening Visit(s):

The Screening Period will last a minimum of 2 to a maximum of 30 days. At the first screening visit (Visit 0), informed consent will be obtained. The Mini International Neuropsychiatric Interview (MINI), with the Manic Module from the MINI plus, will be performed to establish whether the patient meets DSM-IV criteria for bipolar disorder I, II, or NOS, and for panic disorder or generalized anxiety disorder. For generalized anxiety disorder, the portion of Criterion F - that stipulates "the disturbance does not occur exclusively during a mood disorder" will be suspended. The CGI-BP and the CGI-S will be performed to establish the severity of bipolar affective symptoms and anxiety symptoms, respectively. Subjects will keep a mood chart in between visits to help them follow their affective and anxiety symptoms. The subject's bipolar symptoms must be evaluated as no more than moderately severe (defined as a CGI-BP < 4), and his/her anxiety symptoms must be evaluated as at least moderately severe (a CGI-S of > 4) for him/her to be able to continue in the screening process and enter the randomized phase. Medical history will be reviewed, a physical exam performed, electrocardiogram (EKG) and laboratory studies (complete metabolic profile, CBC with differential and platelets, urinalysis, pregnancy test, and urine drug screen) will be obtained. Based on these evaluations, it will be determined whether subjects meet entry criteria; subjects meeting these criteria will continue in the screening process.

Baseline Visit (last Screening Visit):

At baseline (Visit 1), subjects whose screening evaluations continue to meet all inclusion/exclusion criteria may enter the study and be randomized. These evaluations will include repeating the Clinical Global Impression modified for bipolar illness (CGI-BP) and the Clinical Global Improvement Scale for anxiety symptoms (CGI-S) to ensure the subject continues to have no more than moderately severe bipolar affective symptoms and at least moderately severe anxiety symptoms. Baseline ratings will include: the Sheehan Panic Anxiety Scale-Clinician Rated (SPAS-C); the Hamilton Anxiety Scale (HAM-A) to assess anxiety symptoms; the Young Mania Rating Scale (YMRS) to assess manic symptoms; and the Inventory for Depressive Symptoms (IDS) (long form) to assess depressive symptoms. Subjects will also be evaluated with the CGI-BP, and the Sheehan Disability Scale (SDS). The Panic-Agoraphobic Spectrum-Self-Report (PAS-SR) will be used to assess the lifetime presence of core and related features of panic disorder. (Subjects who score > 35 on the PAS-SR will be classified a-priori as having panic spectrum symptoms [PSS]). The Family Impact Scale (FIS) will be administered. The Abnormal Involuntary Movement Scale (AIMS), Simpson Angus Scale (SAS), and Barnes Akathisia Rating Scale (BARS) will be administered to assess for extrapyramidal symptoms. Blood pressure, pulse, height, and weight, will be measured. Study medication will be dispensed by the Physician Investigator in the form of 0.5 mg capsules. The dose range of risperidone will be 0.5 to 4 mg/day.

Treatment Period:

Study visits will occur every week through the eight weeks of treatment. It is expected that risperidone will be gradually increased to an optimal dose during the first month of treatment. The following procedures will be completed at each visit.

1. Collect unused risperidone, perform study drug accountability, and record dosage of study drug used. A subject's unused study medication can be re-dispensed back to the subject.

2. Review mood chart and administer Clinician Global Improvement on anxiety symptoms -21 point scale (CGI-I-21), Patient Global Improvement on anxiety symptoms -21 point scale (PGI-21), SPAS-C, HAM-A, YMRS, IDS, CGI-BP, and SDS ratings.

3. Assess and record adverse events.

4. Perform AIMS, SAS, and BARS.

5. Obtain blood pressure, pulse, and weight.

6. Record concomitant medication use (from mood chart)

7. Adjust risperidone dose (if necessary) and dispense study drug.

Final Evaluation (week 8) or Early Termination:

The following evaluations will be conducted at the completion of, or early withdrawal from, the 8-week treatment phase. All psychiatric evaluations and all other final study procedures (including a repeat physical exam, EKG, and laboratory studies) will be completed prior to the discontinuation of risperidone. The evaluations to be performed are:

- Collect unused risperidone, perform study drug accountability, and record dosage of study drug used.

- Review mood chart and perform CGI-21, SPAS-C, HAM-A, YMRS, IDS, CGI-BP, PGI-21, and SDS ratings.

- Repeat PAS-SR

- Repeat FIS

- Assess and record adverse events.

- Obtain blood pressure, pulse, weight, and determine BMI.

- Perform physical examination, AIMS, SAS, BARS.

- Obtain laboratories (complete metabolic profile, CBC with/differential and platelets, urinalysis, pregnancy test, and urine drug screen).

- Repeat EKG.

- Record concomitant medication use (from mood chart)

- Adjust risperidone dose (if necessary) and prescribe drug (if subject has responded and chooses to continue on risperidone), or dispense risperidone taper for discontinuation (if subject has not responded or if subject chooses to discontinue risperidone for any reason).

Study Design

Allocation: Randomized, Control: Placebo Control, Intervention Model: Parallel Assignment, Masking: Double-Blind


Bipolar Disorder




University of Cincinnati Medical Center
United States




Lindner Center of HOPE

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:46:43-0400

Clinical Trials [1310 Associated Clinical Trials listed on BioPortfolio]

A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence

The purpose of this study is to determine whether quetiapine or risperidone are effective in treating mood symptoms, drug cravings and use in bipolar disorder with concurrent cocaine or me...

Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder

The objectives of this study are to study the safety, effectiveness, tolerability and dosing regimen of risperidone, and olanzapine, in the treatment of mania in Bipolar Disorder I and Bip...

A Study to Evaluate the Effectiveness and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder.

The purpose of the study is to evaluate the efficacy of risperidone long-acting injectable in comparison with placebo in the prevention of a mood episode in treatment of patients with bipo...

Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients

The purpose of this study is to determine whether the sedating (causing sleepiness) effects of risperidone or quetiapine alter cognitive (person's ability to think, perceive, recognize, re...

Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder

The primary objective is to evaluate the safety and efficacy of divalproex extended release (ER) compared to risperidone in the treatment of bipolar disorder with comorbid substance use di...

PubMed Articles [4730 Associated PubMed Articles listed on BioPortfolio]

Agitated depression in bipolar disorder.

It has been suggested that agitated depression (AD) is a common, severe feature in bipolar disorder. We aimed to estimate the prevalence of AD and investigate whether presence of AD was associated wit...

Metacognitive functioning in bipolar disorder versus controls and its correlations with neurocognitive functioning in a cross-sectional design.

Metacognition is an important factor in the development and persistence of bipolar disorder. One of the most striking examples of impairment in metacognitive functioning in bipolar disorder is the lac...

An International Society of Bipolar Disorders Task force Report: Precursors and Prodromes of Bipolar Disorder.

To clarify the clinical features preceding the onset of Bipolar disorder (BD) has become a public health priority for the prevention of high morbidity and mortality. BD remains frequently under- or mi...

Lithium prophylaxis in early-onset Bipolar disorder: a descriptive study.

Subjects fulfilling DSM 5 criteria of Bipolar I disorder with onset before 18 years on Lithium prophylaxis were included. A total of 575 subjects with Bipolar Disorder were screened, 141 had early-ons...

A linkage and exome study implicates rare variants of KANK4 and CAP2 in bipolar disorder in a multiplex family.

Bipolar disorder (BPD) is a neuropsychiatric disorder with a complex pattern of inheritance. Although many genetic studies have been conducted on BPD, its genetic correlates remain uncertain. This stu...

Medical and Biotech [MESH] Definitions

A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.

A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.

An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight 6.94. Salts of lithium are used in treating BIPOLAR DISORDER.

INTERNEURONS of the vertebrate RETINA containing two processes. They receive inputs from the RETINAL PHOTORECEPTOR CELLS and send outputs to the RETINAL GANGLION CELLS. The bipolar cells also make lateral connections in the retina with the RETINAL HORIZONTAL CELLS and with the AMACRINE CELLS.

A thiazole derivative and atypical ANTIPSYCHOTIC AGENT that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST; SEROTONIN 5-HT2 RECEPTOR ANTAGONIST, serotonin 5-HT7 receptor antagonist, and antagonist of the adrenergic α2A and α2C receptors, as well as a partial SEROTONIN 5-HT1A RECEPTOR AGONIST. It is used in the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER.

More From BioPortfolio on "Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Searches Linking to this Trial